Compare NRDS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRDS | SGMT |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.8M | 761.6M |
| IPO Year | 2021 | 2021 |
| Metric | NRDS | SGMT |
|---|---|---|
| Price | $7.50 | $10.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $10.13 | ★ $27.91 |
| AVG Volume (30 Days) | 967.8K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.42 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $836,600,000.00 | $2,000,000.00 |
| Revenue This Year | $4.52 | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $12.38 | ★ N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $7.26 | $4.50 |
| 52 Week High | $16.24 | $11.45 |
| Indicator | NRDS | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 52.15 |
| Support Level | N/A | $9.95 |
| Resistance Level | $10.16 | $11.23 |
| Average True Range (ATR) | 0.57 | 0.71 |
| MACD | -0.45 | 0.10 |
| Stochastic Oscillator | 5.72 | 51.24 |
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.